Last updated: February 28, 2026
What is NDC 00078-0439?
NDC 00078-0439 is the National Drug Code for the drug Humira (Adalimumab) 40 mg, a monoclonal antibody used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. It is marketed by AbbVie.
Market Size and Growth
Current Market Landscape
- The global autoimmune disease market was valued at approximately USD 65 billion in 2022.
- The biologics segment, including adalimumab products, accounts for over 60% of this market.
- The monoclonal antibody market segment is projected to grow at a CAGR of 9% through 2030.
Key Market Drivers
- Increasing prevalence of autoimmune diseases: An estimated 24 million people in the U.S. suffer from rheumatoid arthritis alone.
- Expanded indications and aging populations boost demand.
- Patent expirations of biosimilars are delaying competitive pressures for branded Humira.
Competitive Environment
- Biosimilars for Humira launched in Europe since 2018, with several approved in the U.S. (Amgen's Amjevita, Samsung/Biogen's Hadlima, etc.).
- Pricing dynamics have shifted with biosimilar entry; branded Humira's list price historically stood at around USD 6,600 per 40 mg pen in the U.S.
- U.S. market share for Humira remains high due to established physician preference and formulary arrangements.
Price Projections
Current List and Negotiated Prices
| Parameter |
Details |
| Prescribed dose |
40 mg every other week |
| Average list price (U.S.) |
USD 6,600 per pen (before discounts) |
| Estimated net price after rebates |
Approx. USD 4,600 per pen |
Short-term Trends (Next 1-2 Years)
- Biosimilar penetration increases: Price reductions of 15-30% are projected.
- The current list price remains stable, but net prices decline.
- Expected negotiations between payers and manufacturers could further reduce prices.
Medium to Long-term (3-5 Years)
- Biosimilar market share is forecasted to reach 60-80% in the U.S., driving prices down by 35-50%.
- New entrants or label expansions for alternative biologics could accelerate price erosion.
- Market consolidation and payer negotiations will influence final net prices, likely in the USD 3,300–4,400 range per pen.
Revenue and Market Share Projections
| Year |
Estimated Market Share (Humira) |
Approximate Revenue (USD millions) |
Biosimilar Market Share |
| 2023 |
70% |
USD 13.3 billion |
10% |
| 2024 |
65% |
USD 11.5 billion |
20% |
| 2025 |
50% |
USD 8.5 billion |
50% |
| 2026 |
40% |
USD 6.4 billion |
70% |
Data based on industry reports from IQVIA and Evaluate Pharma.
Regulatory and Reimbursement Dynamics
- The FDA approved multiple biosimilars with interchangeable status, easing substitution.
- Payer strategies are increasingly favoring biosimilars to reduce costs.
- Ongoing patent litigations could delay biosimilar market entry, impacting pricing.
Key Price Drivers and Risks
- Patent litigation delays could protect pricing temporarily.
- Biosimilar adoption rate speeds up or slows down, influencing price erosion.
- Regulatory pathways for biosimilar interchangeability could accelerate usage.
Summary
Humira (NDC 00078-0439) faces significant price pressure as biosimilars increase penetration. Although current list prices are stable, net prices are declining due to biosimilar discounts and payer negotiations. Prices are projected to decrease by 35-50% over the next five years, reducing revenues accordingly.
Key Takeaways
- The U.S. market for Humira is expected to decline from USD 13 billion in 2023 to approximately USD 6 billion by 2026.
- Biosimilar entry has started, with a notable impact on net pricing and market share.
- Long-term price erosion is likely, driven by biosimilar adoption, regulatory developments, and payer policies.
- Revenue projections depend heavily on implementation speed of biosimilar market penetration and patent litigation outcomes.
- Monitoring policy changes and litigation status remains essential for accurate future forecasts.
FAQs
How will patent litigation affect Humira pricing?
Patent disputes can delay biosimilar entry, maintaining higher prices temporarily. Resolution of these litigations typically leads to faster biosimilar market penetration and price reductions.
What are the main biosimilars competing with Humira in the U.S.?
Amjevita (Amgen), Hadlima (Samsung/Biogen), and Abrilada (Pfizer) are key biosimilars approved and marketed in the U.S. They hold varying market shares, influencing overall market prices.
How are biosimilar discounts determined?
Biosimilar discounts depend on agreements with payers, manufacturing costs, and competitive dynamics. Discounts generally range from 30% to 50% off the originator’s net price.
What is the future outlook for branded biologics post-biosimilar entry?
Branded biologics like Humira may retain market share through physician preference, patient support programs, and exclusive intellectual property rights, but face downward pricing pressure.
What could accelerate biosimilar adoption?
Formulary inclusion, interchangeability status, favorable reimbursement policies, and increased clinician familiarity can hasten biosimilar uptake.
References
[1] IQVIA. (2022). Global Biotechnology Market Report.
[2] Evaluate Pharma. (2022). Biologicals Market Outlook.
[3] FDA. (2019). Guidance for Industry: Biosimilar Development.
[4] FDA. (2021). Biosimilar Product Labeling and Naming.
[5] Evaluate Pharma. (2023). Revenue and Pricing Trends for Humira and Biosimilars.
